



FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor

This is the peer reviewed version of the following article:

Original:

Peterlongo, P., Catucci, I., Colombo, M., Caleca, L., Mucaki, E., Bogliolo, M., et al. (2015). FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. HUMAN MOLECULAR GENETICS, 24(18), 5345-5355 [10.1093/hmg/ddv251].

Availability:

This version is available <http://hdl.handle.net/11365/981210> since 2015-11-13T15:17:29Z

Published:

DOI:10.1093/hmg/ddv251

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

***FANCM* c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity, and is a familial breast cancer risk factor**

Paolo Peterlongo^{1,2,*}, Irene Catucci^{1,2}, Mara Colombo², Laura Caleca², Eliseos Mucaki³, Massimo Bogliolo⁴, Maria Marin⁴, Francesca Damiola⁵, Loris Bernard^{6,7}, Valeria Pensotti^{1,7}, Sara Volorio^{1,7}, Valentina Dall'Olio^{1,7}, Alfons Meindl⁸, Claus Bartram⁹, Christian Sutter⁹, Harald Surowy^{10,11}, Valérie Sornin⁵, Marie-Gabrielle Dondon^{12,13,14}, Séverine Eon-Marchais^{12,13,14}, Dominique Stoppa-Lyonnet^{15,16,17}, Nadine Andrieu^{12,13,14}, Olga M. Sinilnikova^{5,18}, GENESIS¹⁹, Gillian Mitchell^{20,21}, Paul A. James^{20,21}, Ella Thompson^{21,22}, kConFab²³, SWE-BRCA²⁴, Marina Marchetti²⁵, Cristina Verzeroli²⁵, Carmen Tartari²⁵, Gabriele Capone^{26,27}, Anna Laura Putignano^{26,27}, Maurizio Genuardi^{26,27,28}, Veronica Medici²⁹, Isabella Marchi²⁹, Massimo Federico²⁹, Silvia Tognazzo³⁰, Laura Matricardi³⁰, Simona Agata³⁰, Riccardo Dolcetti³¹, Lara Della Puppa³², Giulia Cini³², Viviana Gismondi³³, Valeria Viassolo³³, Chiara Perfumo³³, Maria Antonietta Mencarelli^{34,35}, Margherita Baldassarri^{34,35}, Bernard Peissel³⁶, Gaia Roversi³⁶, Valentina Silvestri³⁷, Piera Rizzolo³⁷, Francesca Spina³⁸, Caterina Vivanet³⁸, Maria Grazia Tibiletti³⁹, Maria Adelaide Caligo⁴⁰, Gaetana Gambino⁴⁰, Stefania Tommasi⁴¹, Brunella Pilato⁴¹, Carlo Tondini⁴², Chiara Corna⁴², Bernardo Bonanni⁴³, Monica Barile⁴³, Ana Osorio^{44,45}, Javier Benitez^{44,45}, Luisa Balestrino³⁸, Laura Ottini³⁷, Siranoush Manoukian³⁶, Marco A. Pierotti⁴⁶, Alessandra Renieri^{34,35}, Liliana Varesco³³, Fergus J. Couch⁴⁷, Xianshu Wang⁴⁷, Peter Devilee⁴⁸, Florentine S. Hilbers⁴⁸, Christi J. van Asperen⁴⁹, Alessandra Viel³², Marco Montagna³⁰, Laura Cortesi²⁹, Orland Diez⁵⁰, Judith Balmaña⁵¹, Jan Hauke⁵², Rita K. Schmutzler⁵², Laura Papi²⁶, Miguel Angel

Pujana⁵³, Conxi Lázaro⁵³, Anna Falanga²⁵, Kenneth Offit⁵⁴, Joseph Vijai⁵⁴, Ian Campbell^{21,22,55}, Barbara Burwinkel^{10,11}, Anders Kvist⁵⁶, Hans Ehrencrona⁵⁷, Sylvie Mazoyer⁵, Sara Pizzamiglio⁵⁸, Paolo Verderio⁵⁸, Jordi Surralles⁴, Peter K. Rogan³, Paolo Radice^{1,2}

¹IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy

²Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

³Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London Ontario, Canada

⁴Genome Instability and DNA Repair Group, Department of Genetics and Microbiology, Universitat Autònoma de Barcelona and Center for Biomedical Network Research on Rare Diseases (CIBERER), Barcelona, Spain

⁵Cancer Research Centre of Lyon, CNRS UMR5286, INSERM U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France

⁶Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy

⁷Cogentech, Cancer Genetic Test Laboratory, Milan, Italy

⁸Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany

⁹Institute of Human Genetics, University of Heidelberg, Germany

¹⁰Molecular Biology of Breast Cancer, Department of Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany

¹¹Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany

¹²INSERM, U900, Paris, France

¹³Institut Curie, Paris, France

¹⁴Mines ParisTech, Fontainebleau, France

¹⁵Institut Curie, Service de Génétique Oncologique, Paris, France

¹⁶INSERM, U830, Paris, France

¹⁷Université Paris-Descartes, Paris, France

¹⁸Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre

Hospitalier Universitaire de Lyon / Centre Léon Bérard, Lyon, France

¹⁹A full list of collaborators is provided in the Supplementary Note.

²⁰Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

²¹Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia

²²Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

²³Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

²⁴The Swedish BRCA1 & BRCA2 study collaborators; a full list of collaborators is provided in the Supplementary Note

²⁵Department of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

²⁶Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università di Firenze, Italy

²⁷FiorGen Foundation for Pharmacogenomics, Sesto Fiorentino, Italy

²⁸Institute of Medical Genetics, “A. Gemelli” School of Medicine, Catholic University, Rome Italy

- ²⁹Dipartimento di Oncologia, Ematologia e Malattie dell'Apparato Respiratorio, Università di Modena e Reggio Emilia, Italy
- ³⁰Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV – IRCCS, Padua, Italy
- ³¹Cancer Bio-Immunotherapy Unit, CRO Aviano National Cancer Institute, Aviano (PN), Italy
- ³²Unit of Experimental Oncology 1, CRO Aviano National Cancer Institute, Aviano (PN), Italy
- ³³Unit of Hereditary Cancers, IRCCS AOU San Martino – IST, Genoa, Italy
- ³⁴Medical Genetics, University of Siena, Siena, Italy
- ³⁵Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy
- ³⁶Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- ³⁷Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
- ³⁸SC Medical Genetics, ASl8 Cagliari, Cagliari, Italy
- ³⁹Unit of Pathology, Ospedale di Circolo, Varese, Italy
- ⁴⁰Section of Genetic Oncology, University Hospital and University of Pisa, Pisa, Italy
- ⁴¹IRCCS Istituto Tumori "Giovanni Paolo II", Molecular Genetics Laboratory, Bari, Italy
- ⁴²Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
- ⁴³Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy
- ⁴⁴Human Cancer Genetics Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain

- ⁴⁵Spanish Genotyping Centre (CEGEN), Madrid, Spain
- ⁴⁶Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- ⁴⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
- ⁴⁸Department of Human Genetics, Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
- ⁴⁹Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
- ⁵⁰Oncogenetics Group, Hospital Universitari de la Vall d'Hebron; Vall d'Hebron Institute of Oncology (VHIO); Universitat Autònoma de Barcelona, Barcelona, Spain
- ⁵¹Department of Medical Oncology, Hospital Universitari de la Vall d'Hebron; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- ⁵²Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany
- ⁵³Catalan Institute of Oncology – IDIBELL, Barcelona, Spain
- ⁵⁴Clinical Genetics Service, Department of Medicine and Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, USA
- ⁵⁵Department of Pathology, University of Melbourne, Parkville, Victoria, Australia
- ⁵⁶Department of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden
- ⁵⁷Department of Clinical Genetics, University and Regional Laboratories, Lund University and Skane University Hospital, Lund, Sweden
- ⁵⁸Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

*Corresponding authors: Paolo Peterlongo, IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, via Adamello 16, 20139 – Milan, Italy, Phone: +39.2.57430.3812, Fax: +39.2.57430.3231, E-mail: paolo.peterlongo@ifom.eu

Abstract

Numerous genetic factors that influence breast cancer risk are known. However, approximately two thirds of the overall familial risk remains unexplained. To determine whether some of the missing heritability is due to rare variants conferring high to moderate risk, we tested for an association between the c.5791C>T nonsense mutation (p.Arg1931*; rs144567652) in exon 22 of *FANCM* gene and breast cancer. An analysis of genotyping data from 8,635 familial breast cancer cases and 6,625 controls from different countries yielded an association between the c.5791C>T mutation and breast cancer risk (odds ratio (OR) = 3.93 (95% CI = 1.28–12.11; P = 0.017)). Moreover, we performed two meta-analyses of studies from countries with carriers in both cases and controls, and of all available data. These analyses showed breast cancer associations with OR = 3.67 (95% CI = 1.04–12.87; P = 0.043) and OR = 3.33 (95%CI = 1.09-13.62, P = 0.032), respectively. Based on information theory-based prediction, we established that the mutation caused an out-of-frame deletion of exon 22, due to the creation of a binding site for the pre-mRNA processing protein hnRNP A1. Furthermore, genetic complementation analyses showed that the mutation influenced the DNA repair activity of the *FANCM* protein. In summary, we provide evidence for the first time showing that the common p.Arg1931* loss-of-function variant in *FANCM* is a risk factor for familial breast cancer.

Introduction

Breast cancer (OMIM #114480) is a common oncological disease that accounts for 23% of all malignancies in women and is estimated to cause 1,400,000 new cases and more than 450,000 deaths worldwide every year (1). It has been estimated that approximately 13% of all breast cancer cases have one or more affected relatives, and that risks of breast cancer increase with greater numbers of affected relatives (2). This increased risk is also due to known germ-line susceptibility alleles including rare, high-risk loss of function variants predominantly found in *BRCA1* and *BRCA2* (3). In addition, 94 common single nucleotide polymorphisms (SNPs) have been identified that individually confer only a slightly increased risk of breast cancer, but combined in a multiplicative model account for approximately 16% of familial breast cancer risk (4).

BRCA1 and *BRCA2* gene products contribute to cell homeostasis through the DNA damage response mediated by homologous recombination. Moreover, mutations in *BRCA2* (also known as *FANCD1*) have been shown to cause Fanconi Anemia (FA), a rare recessive disorder characterized by genomic instability, progressive bone marrow failure and predisposition to cancer. These genes encode proteins belonging to the FA pathway, which becomes activated in response to breaks in single and double stranded DNA. Monoallelic variants in several of these genes, including *ATM*, *PALB2/FANCN*, and *RAD51C/FANCO* have been detected in non-*BRCA1* and *BRCA2* familial breast cancer cases, but at a lower frequency in controls, consistent with moderate to high risks of breast cancer (5-7). The rare variants identified in these genes have a cumulative frequency in familial cases of

0.5–2%. However, with the exception of a few recurrent or founder mutations in specific populations, each of these mutations is generally very rare with many reported in single families. In contrast, few rare truncating and pathogenic missense variants have been found in *CHEK2* (8), with much of the risk attributed to this gene explained by the single moderate-penetrance founder allele, c.1100delC (9).

Recent studies have underlined the challenges in identifying new breast cancer predisposition genes. Exome sequencing in families followed by gene re-sequencing in additional cases and controls have provided conflicting results for *XRCC2* (10,11), and inconclusive results for *FANCC* and *BLM* (12), raising questions about the statistical power of these studies (13). Similarly, the evidence that *SLX4*, an FA gene, is associated with breast cancer risk is limited, given that the analysis of large numbers of familial cases identified only three inactivating variants (14-16).

Screening for risk-associated mutations in *BRCA1* and *BRCA2* is commonly used in clinical practice to identify at-risk individuals and to direct them towards specific surveillance programs or risk reduction options. By including additional breast cancer predisposition genes in gene panels analyzed by next-generation sequencing, risk prediction can be performed in a larger fraction of individuals at a reduced cost with rapid turn-around time. With the goal of identifying new risk-associated genes, we and others previously performed exome sequencing in multiple-case breast cancer families (17). One of the findings of that study was a single proband heterozygous for the c.5791C>T variant (rs144567652) in *FANCM*, another gene involved in the FA pathway. The variant was predicted to introduce a stop

codon (TGA) in exon 22, causing the loss of 118 amino-acids from the C-terminus (p.Arg1931*). A subsequent case-control study detected the mutation in 10 of 3,409 (0.29%) familial cases without known mutations in *BRCA1* and *BRCA2*, and in 5 of 3,896 (0.13%) controls from different national studies. The estimated odds ratio (OR) was 2.29 (95% confidence interval (CI) = 0.71–8.54; $P = 0.13$). In an effort to establish the significance of this estimate (17), a further analysis in a larger cohort was performed.

Results

Association with breast cancer risk. We investigated the c.5791C>T mutation in a large series of familial cases without known mutations in *BRCA1* and *BRCA2*, and in a comparable set of control individuals from Italy, France, Spain, Germany, Australia, USA, Sweden and The Netherlands. The mutation was found in 18 of 8,635 (0.21%) cases (pedigrees are shown in Supplementary Figure 1) and in 4 of 6,625 (0.06%) controls (Table 1) giving a statistically significant association with breast cancer with an age-adjusted OR of 3.93 (95%CI = 1.28–12.11; $P = 0.017$). The c.5791C>T mutation is rare and we observed a large variation in allele frequency in cases and controls across studies. To control for population stratification, we performed a meta-analysis, including only studies in which mutation carriers were detected in both cases and controls (Italy, France and Australia). Starting from the ORs and their 95% CIs obtained from a univariate logistic model within each country, we obtained a pooled OR = 3.67; 95% CI = 1.04–12.87; $P = 0.043$) (Table 2). A second meta-analysis was performed by exploiting all the available data. We implemented an exact

conditional logistic regression model including “country” as a random covariate in order to control for population stratification and for the absence of variant carriers in some countries (Sweden and USA) (OR=3.330 (95% CI = 1.087-13.615, P = 0.0320)).

Expression of the mutant allele. To verify the functional consequences of the c.5791C>T mutation, we first performed reverse transcriptase (RT)-PCR in lymphoblastoid cell lines derived from two mutation carriers. Amplifying a product spanning exons 22 and 23, sequence analyses revealed very low levels of the mutated transcript compared to corresponding normal mRNA. Treatment with a protein synthesis inhibitor, cycloheximide, did not alter mutant transcript levels (Figure 1), suggesting that the effect was probably not related to nonsense mediated decay (NMD), but rather to a defect in mRNA splicing itself.

Effect on the mRNA splicing. The occurrence of exonic mutations affecting pre-mRNA splicing is well documented in many human disease genes (18). These include nonsense mutations, a phenomenon referred to by some authors as “nonsense associated altered splicing” (NAS) (19). Therefore, to assess the impact of c.5791C>T on splicing regulatory binding sites controlling exon definition, we performed information theory-based mutation analysis, using the Automated Splice Site and Exon Definition Analysis (ASSEDA) server (20). The variant was predicted to create a strong binding site (information content (R_i) = 4.6 bits) for the splicing factor hnRNP A1 at position c.5790_5795 (21) (Figure 2a). Exon definition analysis suggested that the creation of this site would completely suppress exon recognition ($R_{i,\text{total}}$ from 3.5 to -2.5 bits), predicted to result in exon skipping. This was confirmed by RT-PCR, using forward and reverse primers in exons 21 and 23 which

detected two amplification products (Figure 2b). The upper band derived from the full length transcript (Supplementary Figure 2), while the lower band derived from an aberrant transcript lacking the entire exon 22 (c.5717_6008del292) (Figure 2c). This exon skipping is predicted to encode a protein that incorporates 11 additional residues and a premature termination of translation that results in the loss of 132 amino acids from the FANCM C-terminus (p.Gly1906Alafs12*).

Skipping of exon 22 is mediated by hnRNP A1. A pull-down experiment with HeLa cell extracts followed by Western blot analysis showed that the hnRNP A1 protein specifically bound to RNA oligonucleotides spanning *FANCM* position r.5779_5804 and carrying the r.5791C>U mutation, whereas a very weak interaction was observed with the corresponding normal oligonucleotide (Figure 2d). These results are in agreement with the outcomes of the *in silico* analyses and provide evidence that the mechanism through which the c.5791C>T mutation causes exon 22 skipping is mediated by the binding of hnRNP A1 protein.

DNA repair activity-based functional studies. We then checked whether the c.5791C>T mutation ($\Delta 22$) affects FANCM activity in DNA repair, by genetic complementation of the following FA-associated cell phenotypes: hypersensitivity to MMC and DEB-induced chromosome fragility. As an internal control, we used a previously described nonsense mutation (p.S724X; rs137852864) (22) that leads to a premature stop codon (stop). Mutant cDNAs were generated by site-directed mutagenesis and cloned into lentiviral vectors to stably transduce *Fancm* $-/-$ immortalized mouse embryonic fibroblast (MEFs). Wild type, $\Delta 22$ and stop alleles were expressed at similar levels in infected cells (Supplementary Figure 3). As

expected, wt FANCM but not the prematurely truncated forms rescued MMC hypersensitivity of *Fancm*^{-/-} MEFs (Figure 3a). Similar results were observed in a chromosome fragility assay (Figure 3b). These observations lead to the conclusion that the $\Delta 22$ form of FANCM is deficient in DNA repair of MMC- and DEB- induced stalled replication forks.

Discussion

Genotyping of the c.5791C>T variant from *FANCM* in 8,635 familial cases with no mutations in *BRCA1* and *BRCA2* and in 6,625 control individuals from Italy, France, Spain, Germany, Australia, USA, Sweden and The Netherlands indicate that the variant is associated with risk of breast cancer with OR of 3.93. The association between the variant and breast cancer risk is reinforced if the data from the present case-control analysis are combined with those of Gracia-Aznarez *et al.* (17). Overall, the variant was detected in 28 of 12,044 (0.23%) familial cases and 9 of 10,521 (0.09%) controls, corresponding to a naive OR, adjusted for the “study” covariate, of 2.83 (95% CI = 1.33–6.01, $P = 0.007$). It has to be noted that these studies were based on cases with positive family history for breast cancer and/or disease early onset. These selected cases are likely to be enriched in predisposing genetic factors. Consequently, the ORs observed here could be higher than those expected in unselected cases and population controls.

Population stratification may occur when a rare mutation is tested in individuals from different countries. We took into consideration this critical issue by

performing two meta-analyses. The first was based only on studies with carriers in both cases and controls, while the second exploited all the individual data. Both analyses supported the c.5791C>T mutation as a breast cancer risk factor (OR = 3,67 and OR = 3,33 respectively), although with borderline statistical significance. However, these analyses do not completely guard against stratification effect. Hence, these results need to be taken with caution. In this light, genotyping of additional variants in much larger series of unselected breast cancer cases and matched controls will be needed to confirm *FANCM* as a breast cancer susceptibility gene.

The functional characterization of the mRNA transcript derived from the c.5791C>T allele shows that the variant causes the skipping of exon 22 introducing a premature stop codon. In addition, genetic complementation assays revealed the mutated protein lacks DNA repair activity. These results support the notion that the *FANCM* c.5791C>T mutation is pathogenic. Of note, our observations at the mRNA level emphasize the notion that, although nonsense mutations are usually considered as inherently deleterious, transcript analyses are required for a precise assessment of actual functional consequences.

Interestingly, while this manuscript was in preparation, another *FANCM* C-terminus truncating mutation, the c.5101C>T (p.Q1701*), was detected by the exome sequencing of 11 Finnish breast cancer families (23). The c.5101C>T mutation was shown to be significantly more frequent in Finnish breast cancer cases compared to controls (OR = 1.86; 95% CI = 1.26–2.75; $P = 0.0018$), to have higher effect in cases with family history (OR = 2.11; 95% CI = 1.34–3.32; $P = 0.0012$)—although incomplete co-segregation with the disease was observed among most of the

families—and with the stronger effect (OR = 3.56; 95% CI = 1.81–6.98; P = 0.0002) in mutation carriers affected with triple-negative (estrogen receptor- progesterone receptor- and HER2-negative) breast cancer (TNBC). In addition, the age at breast cancer diagnosis was not different between variant carriers and non-carriers and the variant allele was not subjected to mRNA NMD (23). Among the cases we studied, there were no significant differences in age at breast cancer diagnosis in the 18 variant carriers versus the non-carriers (data not shown). Moreover, because variant carriers with TNBC were not found, it was not possible to associate the c.5791C>T mutation with this specific tumor subtype (see Supplementary Table 1: Information on clinical and molecular phenotype of breast tumor of mutation carriers). Our data, together with the observations by Kiiski *et al.* support the notion that loss-of-function mutations of *FANCM* are moderate breast cancer risk factors. Additional studies, such as modified segregation-analysis in families, are warranted to provide age-specific risk estimates for *FANCM* mutation carriers.

The 1100delC allele of *CHEK2* has a number of properties similar to c.5791C>T in *FANCM*. This allele has been shown to be associated with moderate risk and has been found in many countries with a frequency that is higher in North-Eastern Europe and decreases in Southern Europe (9). Taking into consideration the geographic origin of the individuals included in our study, we observed that the frequency of the mutation carriers in South-Western European countries (16/7,638 = 0.21%) was higher, although with borderline statistical significance (Fisher's exact test $P = 0.052$), than that observed in all other countries evaluated (6/7,622 = 0.08%) (Table 1). This suggests this *FANCM* mutation has a frequency gradient that is opposite of that reported for the *CHEK2* 1100delC. Nevertheless, the relatively small

numbers of carriers observed suggests that further analyses in specific populations would be worthwhile. For example, data from the Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: <http://exac.broadinstitute.org>) [March, 2015 accessed], that is collecting exome sequencing data from individuals included in various disease-specific and population genetic studies, indicates that c.5791C>T occurs in the Finnish population with a carrier frequency of nearly 1%.

The FA pathway is generally subdivided into upstream proteins, assembling into the “core complex” and “downstream effectors“. The “core complex” ubiquitinates the FANCI–FANCD2 complex and this activates the pathway coordinating the action of the downstream effectors. The latter include FANCD1/BRCA2, FANCN/PALB2, FANCI/BRIP1, FANCO/RAD51C that are required for DNA repair by homologous recombination and are all breast cancer genes (24). This has suggested that the involvement of FA genes in breast cancer susceptibility could be limited to the FA downstream effectors (24,25). The FANCM protein has different functional domains, including a DEAH translocase domain at the N-terminus, and domains for interaction with proteins mediating DNA binding between amino acids 675 and 790 for interaction with MHF1 and MHF2, and at the C-terminus beyond amino acid 1799, for interaction with FAAP24 (26). Moreover, FANCM-FAAP24-MHF1-MHF2 acts as an independent “anchor complex” that recognizes the damage caused by interstrand crosslinking agents and recruits the FA core complex (26). Furthermore, FANCM is not essential for complete ubiquitination of the FANCI–FANCD2 complex (24,26). Finally, the FANCM/MHF complex has a translocase activity that is independent of the core complex proteins (27). Hence, FANCM has a direct activity in maintaining the DNA integrity that can be

independent of the FA pathway. In this light, it is possible that the increased risk for breast cancer conferred by the c.5791C>T variant is due to a direct impairment of the DNA damage response as for the FA downstream effectors.

BRCA1 and *BRCA2* are established breast cancer risk factors with high penetrance and *PALB2* was also recently shown to confer a high breast cancer risk (28). While these three genes encode for downstream effectors of the FA pathway, their proteins are also involved in other DNA damage responses, including double strand break repair. Thus *BRCA1*, *BRCA2* and *PALB2* exert DNA damage response functions that one can speculate to be of greater magnitude than *FANCM*. Consequently, susceptibility to breast cancer is expected to be higher in *BRCA1*, *BRCA2*, or *PALB2* mutation carriers and lower in carriers of *FANCM* mutations which is in agreement with our data on the c.5791C>T mutation and similar data on the c.5101C>T mutation (23). By analogy, the abrogation of *BRCA1*, *BRCA2* and *PALB2* functions on the one hand, and the abrogation of *FANCM* function on the other, seem to impact FA differentially. It is known that biallelic *BRCA2* and *PALB2* mutations cause FA, and recently initial evidence of the involvement of *BRCA1* mutations in the disease have been documented. *BRCA1* biallelic mutations were found in a woman showing anomalies consistent with a FA-like disorder, which supports *BRCA1/FANCS* as a novel FA gene (29). By contrast, the role of *FANCM* in FA is questionable. The only FA patient reported so far with truncating *FANCM* mutations also carried deleterious mutations in *FANCA* (22; 30). Moreover, individuals homozygous for the truncating *FANCM* mutations c.5101C>T and c.5791C>T did not present with FA (31) indicating that, at present, *FANCM* cannot be considered to cause FA.

In conclusion, based on the analysis of large sets of cases and controls and functional observations, our study provides evidence that the *FANCM* c.5791C>T is a novel risk factor for familial breast cancer.

Materials and Methods

Study populations. Twenty-five case-control cohorts were included in the study through a collaboration call circulated among the COMPLEXO participants (32). Center or Study details, number and description of cases and controls are reported in Supplementary Table 2. The cases included in this study were: i) affected with breast cancer at age ≥ 18 , ii) eligible to *BRCA1*- and *BRCA2*-mutation testing based on breast and/or ovarian cancer family history (at least one 1st or 2nd degree female relatives with either tumors), or because affected with early onset (≤ 40 years) or bilateral (≤ 50 years) breast cancer, and iii) negative to *BRCA1*- and *BRCA2*-mutation test. A few of the Centers or Studies contributing to this paper used slightly different inclusion criteria, these are described in Supplementary Table 2. In all cohorts, cases and controls were female Caucasians recruited in the same area. All individuals included in the study signed an informed consent to the use of their biological samples for research purposes. The participation to this study was approved by Ethical Committees or Review Boards of the participant Centers or Studies.

Mutation genotyping. Details of genotype analyses for *FANCM* (NG_007417.1, NM_020937.2) c.5791C>T mutations are reported in Supplementary Table 2. For

most studies, cases and controls were genotyped at coordinating center (IFOM, Milano) by custom TaqMan SNP genotyping assay (Life Technologies) using the following primers and probes. Forward primer: 5'-AGCCTGCTGACTACCTTAATTGG-3'; reverse primer: 5'-CTTTAGCAAATCTGCGGTTTCTTCT-3'; probe 1: 5'-TGAAAAGAATTCGGATTCC-3'; probe 2: 5'-TGAAAAGAATTCAGATTCC-3'.

In every 96-well plate at least one positive control and two blank controls were included. The remaining samples were genotyped at local centers using TaqMan assay or high-resolution melting. All positive samples were confirmed by double-strand Sanger sequencing. Two Studies (SWE-BRCA and MAYO) provided genotyping data from previous next generation sequencing studies.

Statistical analyses. Logistic regression analysis was used to test the association between mutation frequencies and risk of breast cancer (33). Age was included in the model as adjustment covariate and the adjusted odds ratio (ORs) and its 95% confidence intervals (CI), were estimated. A meta analysis considering only countries in which mutation carriers were observed in both cases and controls was performed based on mixed models (34) starting from single-study estimates. A meta-analysis exploiting all individual data was performed using an exact conditional logistic regression model (35). The statistical analyses were performed with the SAS software (Version 9.2; SAS Institute Inc. Cary, NC).

Information theory-based mutation analyses. The ASSEDA server (<http://mutationforecaster.com>) has been developed to predict the molecular phenotype of putative splicing mutations (20) and implemented to take into account

their effect on splicing factor binding sites. In particular, CLIP-seq libraries for hnRNP A1 (36) were used to derive information theory-based position weight matrix (PWM), depicted in Figure 2a. PoWeMaGen software, which uses Bipad (36) to generate minimum entropy alignments, generates a series of potential binding site models over a range of input parameters. To mitigate against phasing the alignment on natural splice sites instead of adjacent hnRNP A1 binding sites, models were built from shorter sequences, ranging in lengths between 18 and 25 nucleotides (nt). The optimal model was determined by maximizing incremental information by varying binding site length (6–10 nt), number of Monte Carlo cycles (250–5000), and allowing either zero or only one site per sequence (OOPS). The model with the highest average information used a maximum fragment length of 18 nt, 1000 Monte Carlo cycles, OOPS, and a single block binding site length of 6 nt. This sequence is frequently present in sites crosslinked to hnRNP A1 protein (34). Of the 140,431 hnRNP A1 binding sites used to create the information theory-based model, the wild type sequence, CCGAAT, is not represented, and the mutant site, CTGAAT, occurred 716 times. The model was validated with known hnRNP A1 binding sites and splicing affecting mutations (38-41). The effects of mutations at hnRNP A1 sites on exon definition were determined from the total information content ($R_{i,\text{total}}$), by incorporating changes in the strengths of these sites, corrected for the gap surprisal, which represents the distance between the hnRNP A1 site and the natural splice site. Gap surprisal values were determined by scanning the genome for hnRNP A1 sites with the PWM, and then determining the frequency of each interval length between known natural sites and the nearest hnRNP A1 site, separately for exons and introns. Differences between the natural and mutated exon $R_{i,\text{total}}$ values correspond to changes in the abundance of the respective isoforms, and can predict exon skipping. The

calculation is carried out by the ASSEDA server (20). Exon definition analysis was validated for a set of mutations that affect hnRNP A1 binding site strength (39,40).

Cell Lines. Epstein_Barr virus (EBV)-immortalized human lymphoblastoid cell lines (LCLs) were established from peripheral blood derived from two carriers of the c.5791C>T mutation and ten normal controls (42). LCLs were maintained in RPMI 1640 medium supplemented with 15% fetal bovine serum plus 1% penicillin-streptomycin. The HeLa cell line was cultured in DMEM medium supplemented with 10% fetal calf serum plus 1% penicillin-streptomycin at 37°C in a humidified 5% CO₂ atmosphere. The HeLa cell line was authenticated by short tandem repeat analysis using the kit GenePrint10 kit (Promega). *Fancm*^{-/-} immortalized MEFs (43) were a kind gift of Dr. H. Te Riele from The Netherlands Cancer Institute, Amsterdam. MEFs were cultured in DMEM 10% FCS supplemented with antibiotics. All the cell lines used in this study were routinely checked for mycoplasma contamination using the PCR Mycoplasma Detection Set (Takara) or the MycoAlert™ Mycoplasma Detection Kit (Lonza).

Transcript analyses. Potential degradation of unstable transcripts containing premature termination codons via nonsense mediated mRNA decay (NMD) was prevented by growing LCLs in the presence of cycloheximide (100µg/ml) for 4 h. Total RNA was purified from LCLs using the Nucleospin RNA II (Macherey-Nagel) and the cDNA was synthesized using random primer and Maxima H Minus Enzyme (Thermo Scientific), according to the manufacturers' protocols. cDNAs were PCR-amplified using the following primers. Exon 21, forward: 5'-CAAGTTCATTGAGCAGATCCAG-3'; exon 22, forward: 5'-

ACATCAAGGATGTTTAGGA-3'; exon 22, reverse: 5'-GTGCCTCACTTTTACTTA-3'; exon 23, reverse: 5'-CCCATCTTGAGCAGCTTGA-3'. Amplification products were visualized on agarose gel stained with ethidium bromide and directly characterized by Sanger sequencing. Alternatively, single PCR fragments were excised from the gel, purified using the Wizard® SW Gel and PCR Clean-Up System (Promega) and sequenced.

Biotin RNA-Protein pull down assay. Protein extraction was performed starting from approximately 5×10^6 HeLa cells. These cells were harvested by centrifugation at 4°C for 5 min, washed twice with 1X PBS and lysed in Lysis Buffer, [25mM Tris (pH 7.4), 150mM NaCl, 1mM EDTA, 1% Nonidet P-40, 5% Glycerol] containing protease inhibitor (Sigma-Aldrich), on ice for 30 min. Following centrifugation, the protein concentration was determined by Bradford assay (Bio-Rad). Mutated and normal RNA oligonucleotides were biotinylated at the 3' end using the RNA 3' End Desthiobiotinylation Kit (Thermo Scientific Pierce), according to the manufacturer's instructions. For each binding reaction, 50 pmol of biotinylated RNA oligonucleotides were coupled to 50 µl of Streptavidin Magnetic Beads (Thermo Scientific Pierce) and incubated with an equal amount of HeLa cell lysates in 1X Protein-RNA Binding Buffer [0.2M Tris (pH 7.5), 0.5M NaCl, 20mM MgCl₂, 1% Tween-20 Detergent], for 2 h at 4°C with agitation. The bound proteins were eluted from the magnetic beads by incubating with 50 µl of Biotin Elution Buffer (Thermo Scientific Pierce) for 30 min at 37°C with agitation. The eluted proteins were subjected to 4-15% SDS-PAGE gradient gel and visualized by Western blotting using a goat polyclonal antibody against hnRNP-A1 (#sc-10029, Santa Cruz Biotechnology), or a mouse monoclonal antibody against ELAVL1/HuR (#1862775, Thermo Scientific Pierce). The binding

site for the ELAVL1/HuR protein was identified with ASSEDA (<http://splice.uwo.ca/logos.html>).

Plasmids used for functional studies. The doxycycline-inducible lentiviral vector pLVX-TRE3G-FANCM was kindly provided by Dr. N. Ameziane (Vrije Universiteit Medical Center, Amsterdam, The Netherlands) and mutated by site directed mutagenesis with the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) as previously described (42) and using the following PAGE purified mutagenic primers. $\Delta 22$ primer 1: 5'-

GAAAAGGACAGAGAAAAACAGCTCACTTCAAGAAATCTCCATG-3', $\Delta 22$

primer 2: 5'-CATGGAGATTTCTTGAAGTGAGCTGTTTTTCTCTGTCCTTTTC-

3', c.2171C>A primer 1: 5'-

TGAGGAAAACAAACCAGCTCAAGAATAAACCACTGGAATTC-3', c.2171C>A

primer 2: 5'-GAATTCCAGTGGTTTATTCTTGAGCTGGTTTGTTCCTCA-3'.

The sequences of all *FANCM* constructs were verified by Sanger sequencing to confirm that they only bore the intended mutations.

Lentiviral particles production and cell transduction. To prepare lentiviral particles 5×10^6 HEK-293T cells were plated into 10-cm dishes. The next day, medium was changed with a fresh one containing 30 μ M Chloroquine (Sigma) and cells were transfected with the lentiviral expression vectors and the helper plasmids (PAX and ENV) using the CalPhos Mammalian Transfection Kit (Clontech). The medium was changed 24 h after transfection and 24 h later the lentivirus-containing supernatant was collected and filtered through a 0.45 μ m filter (Millipore). Additional supernatant was collected after additional 24 h, filtered and pooled with the initial one. Pooled

supernatants were centrifuged in a Beckman JS-24.38 rotor at 19,500 rpm for 1.5 h at 4°C. Pellets were resuspended in PBS (50µl of PBS/10 ml of supernatant) and stored at -80°C. Sixty thousands of *Fancm*^{-/-} MEFs per well were seeded in a 12 well plate. After 24 h, cells were infected with 20 µl of concentrated viral supernatant in the presence of 1 µg/ml polybrene (Millipore). Twenty-four h later, infected cells were selected with Puromycin (2.5 µg/ml). Transgene expressions were checked by real-time PCR.

MMC sensitivity test. Twenty-five thousand cells of each cell line were seeded in 2 ml of complete medium supplemented with 2 µg/ml Doxycycline in 12 wells of 6-well plates. The next day, MMC was added at the indicated doses and the cell sensitivity was evaluated 72 h after cell cultures were washed with PBS. Cells were collected in a volume of 300 µl of Trypsin and 700 µl of complete medium and counted with a Z2™ coulter counter (Beckman Coulter) (44).

Chromosome fragility test. Two hundred thousand cells were seeded in complete medium supplemented with 2 µg/ml doxycycline. Twenty-four h later, diepoxybutane (DEB) was added at the indicated concentrations, and metaphase spreads were then harvested 3 days later as it follows. Colcemid™ (Sigma) was added at 0.1 µg/ml final concentration and after 2 h cells were trypsinized, washed in PBS, the pellet was resuspended in hypotonic solution (0.075 M KCl) and incubated for 25 min at 37°C. Cells were then washed three times with methanol:acetic acid (4:1) and the cell suspension was dropped on microscope slides and Giemsa stained. Twenty metaphase cells from each DEB concentration were scored for chromosome breakage after image capture using the Metafer Slide Scanning Platform from Metasystems (45).

Acknowledgements

The authors wish to thank all the individuals who took part in this study. We also wish to thank Antonis Antoniou (University of Cambridge) for helpful discussion, Claudia Foglia (INT) for DNA preparation, Fernando Ravagnani (INT) for recruitment of blood donors and Donata Penso (INT) for cell lines authentication; Roser Pujol and Maria Jose Ramirez (CIBERER/UAB) for cytogenetic analysis; Victoria Fernandez (CNIO) for the genotyping study; Gabriel Capella (Hereditary Cancer Program ICO) for the clinical and molecular work done in identifying and genotyping breast cancer patients; Peter Bugert (University of Heidelberg) for collecting control samples, Rongxi Yang and Katharina Mattes for supporting the genotyping; all the collaborating cancer clinics of the French National Study GENESIS (GENE SISTers), M. Marcou, D. Le Gal, L. Toulemonde, J. Beauvallet, N. Mebirouk, E. Cavaciuti, A. Fescia (genetic epidemiology platform The PIGE, Plateforme d'Investigation en Génétique et Epidémiologie), C. Verny-Pierre and L. Barjhoux (Biological Resource Centre); H. te Riele and N. Ameziane for sharing materials.

This study was partially supported by funds from “Ricerca Finalizzata – Bando 2010” from Ministero della Salute, Italy to P. Peterlongo and C. Tondini, Associazione Italiana per la Ricerca sul Cancro (AIRC - IG 12821) to P. Peterlongo, (IG 12780) to L. Ottini and (IG 5706) to L. Varesco, Italian citizens who allocated a 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori to S.

Manoukian and P. Radice, of the CRO Aviano National Cancer Institute to A. Viel, and of the Istituto Oncologico Veneto IOV – IRCCS to M. Montagna, according to Italian law and Fondazione Italiana per la Ricerca sul Cancro” (FIRC - triennial fellowship “Armanda e Enrivo Mirto”) to I. Catucci and (triennial fellowship "Mario e Valeria Rindi") to V. Silvestri; National Institutes of Health (NIH, CA128978, CA116167, CA176785) and the Breast Cancer Research Foundation to F. Couch; Spanish Network on Rare Diseases (CIBERER) and the PI12/00070; the Spanish Carlos III Health Institute (FIS project PI12/02585) to O. Diez; Asociación Española Contra el Cáncer, Spanish Health Research Foundation, Ramón Areces Foundation, Catalan Health Institute and Autonomous Government of Catalonia (ISCIIRETIC RD12/0036/008, PI10/01422, PI12/01528, PI13/00285, 2009SGR290 and 2009SGR283); the Swedish Cancer Society, Berta Kamprad Foundation, Gunnar Nilsson Foundation, BioCARE and the Swedish Society of Medicine; UNICANCER, the Ligue Nationale Contre le Cancer and the French National Institute of Cancer (INCa); MINECO (SAF2012-31881), ICREA Academia, Generalitat de Catalunya (SGR0489-2009, SGR317-2014) and European Regional Development FEDER Funds to J. Surrallés; Canadian Breast Cancer Foundation, Canadian Foundation for Innovation, Canada Research Chairs Secretariat and the Natural Sciences and Engineering Research Council of Canada (NSERC Discovery Grant 371758-2009) to P. Rogan.

Conflict of interest

Peter Rogan is the inventor of US Patent 5,867,402 and other patents pending, which predict and validate mutations. He is one of the founders of Cytognomix, Inc. (London ON) which creates software based on this technology. All the others authors declare no conflict of interest.

References

1. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int. J. Cancer*, **127**, 2893-2917.
2. Collaborative Group on Hormonal Factors in Breast Cancer. (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet*, **358**, 1389-1399.
3. Mavaddat, N., Antoniou, A.C., Easton, D.F. and Garcia-Closas, M. (2010) Genetic susceptibility to breast cancer. *Mol. Oncol.*, **4**, 174-191.
4. Michailidou, K., Beesley, J., Lindstrom, S., Canisius, S., Dennis, J., Lush, M.J., Maranian, M.J., Bolla, M.K., Wang, Q., Shah, M., et al. (2015) Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nat. Genet.*, **47**, 373-380.
5. Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., North, B., Jayatilake, H., Barfoot, R., Spanova, K. *et al.* (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat. Genet.*, **38**, 873-875.

6. Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., Chagtai, T. *et al.* (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat. Genet.*, **39**, 165-167.
7. Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund, M., Lichtner, P., Hartmann, L., Schaal, H. *et al.* (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nat. Genet.*, **42**, 410-414.
8. Le Calvez-Kelm, F., Lesueur, F., Damiola, F., Vallee, M., Voegelé, C., Babikyan, D., Durand, G., Forey, N., McKay-Chopin, S., Robinot, N. *et al.* (2011) Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. *Breast Cancer Res.*, **13**, R6.
9. Weischer, M., Bojesen, S.E., Ellervik, C., Tybjaerg-Hansen, A. and Nordestgaard, B.G. (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. *J. Clin. Oncol.*, **26**, 542-548.
10. Park, D.J., Lesueur, F., Nguyen-Dumont, T., Pertesi, M., Odefrey, F., Hammet, F., Neuhausen, S.L., John, E.M., Andrulis, I.L., Terry, M.B. *et al.* (2012) Rare mutations in XRCC2 increase the risk of breast cancer. *Am. J. Hum. Genet.*, **90**, 734-739.
11. Hilbers, F.S., Wijnen, J.T., Hoogerbrugge, N., Oosterwijk, J.C., Collee, M.J., Peterlongo, P., Radice, P., Manoukian, S., Feroce, I., Capra, F. *et al.* (2012) Rare variants in XRCC2 as breast cancer susceptibility alleles. *J. Med. Genet.*, **49**, 618-620.

12. Thompson, E.R., Doyle, M.A., Ryland, G.L., Rowley, S.M., Choong, D.Y., Tothill, R.W., Thorne, H., Barnes, D.R., Li, J., Ellul, J. *et al.* (2012) Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. *PLoS Genet.*, **8**, e1002894.
13. Ellis, N.A. and Offit, K. (2012) Heterozygous mutations in DNA repair genes and hereditary breast cancer: a question of power. *PLoS Genet.*, **8**, e1003008.
14. Bakker, J.L., van Mil, S.E., Crossan, G., Sabbaghian, N., De Leeneer, K., Poppe, B., Adank, M., Gille, H., Verheul, H., Meijers-Heijboer, H. *et al.* (2013) Analysis of the novel fanconi anemia gene SLX4/FANCP in familial breast cancer cases. *Hum. Mutat.*, **34**, 70-73.
15. de Garibay, G.R., Diaz, A., Gavina, B., Romero, A., Garre, P., Vega, A., Blanco, A., Tosar, A., Diez, O., Perez-Segura, P. *et al.* (2013) Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families. *Eur. J. Hum. Genet.*, **21**, 883-886.
16. Shah, S., Kim, Y., Ostrovnaya, I., Murali, R., Schrader, K.A., Lach, F.P., Sarrel, K., Rau-Murthy, R., Hansen, N., Zhang, L. *et al.* (2013) Assessment of SLX4 Mutations in Hereditary Breast Cancers. *PLoS One*, **8**, e66961.
17. Gracia-Aznarez, F.J., Fernandez, V., Pita, G., Peterlongo, P., Dominguez, O., de la Hoya, M., Duran, M., Osorio, A., Moreno, L., Gonzalez-Neira, A. *et al.* (2013) Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. *PLoS One*, **8**, e55681.
18. Wang, G.S. and Cooper, T.A. (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. *Nat. Rev. Genet.*, **8**, 749-761.

19. Sterne-Weiler, T., Howard, J., Mort, M., Cooper, D.N. and Sanford, J.R. (2011) Loss of exon identity is a common mechanism of human inherited disease. *Genome Res.*, **21**, 1563-1571.
20. Mucaki, E.J., Shirley, B.C. and Rogan, P.K. (2013) Prediction of mutant mRNA splice isoforms by information theory-based exon definition. *Hum. Mutat.*, **34**, 557-565.
21. Caceres, J.F., Stamm, S., Helfman, D.M. and Krainer, A.R. (1994) Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. *Science*, **265**, 1706-1709.
22. Meetei, A.R., Medhurst, A.L., Ling, C., Xue, Y., Singh, T.R., Bier, P., Steltenpool, J., Stone, S., Dokal, I., Mathew, C.G. *et al.* (2005) A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. *Nat. Genet.*, **37**, 958-963.
23. Kiiski, J.I., Pelttari, L.M., Khan, S., Freysteinsdottir, E.S., Reynisdottir, I., Hart, S.N., Shimelis, H., Vilske, S., Kallioniemi, A., Schleutker, J. *et al.* (2014) Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. *Proc. Natl. Acad. Sci.*, **111**, 15172-15177.
24. Kottemann, M.C. and Smogorzewska, A. (2013) Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. *Nature*, **493**, 356-363.
25. Tischkowitz, M. and Xia, B. (2010) PALB2/FANCN: recombining cancer and Fanconi anemia. *Cancer Res.*, **70**, 7353-7359.
26. Walden, H. and Deans, A.J. (2014) The Fanconi anemia DNA repair pathway: structural and functional insights into a complex disorder. *Annu. Rev. Biophys.*, **43**, 257-278.

27. Huang, J., Liu, S., Bellani, M.A., Thazhathveetil, A.K., Ling, C., de Winter, J.P., Wang, Y., Wang, W. and Seidman, M.M. (2013) The DNA translocase FANCM/MHF promotes replication traverse of DNA interstrand crosslinks. *Mol. Cell*, **52**, 434-446.
28. Antoniou, A.C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkas, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F. *et al.* (2014) Breast-cancer risk in families with mutations in PALB2. *N. Engl. J. Med.*, **371**, 497-506.
29. Sawyer, S.L., Tian, L., Kähkönen, M., Schwartzentruber, J., Kircher, M.; University of Washington Centre for Mendelian Genomics; FORGE Canada Consortium, Majewski, J., Dymont, D.A., Innes, A.M. *et al.* (2015) Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. *Cancer Discov.*, **5**, 135-42.
30. Singh, T.R., Bakker, S.T., Agarwal, S., Jansen, M., Grassman, E., Godthelp, B.C., Ali, A.M., Du, C.H., Rooimans, M.A., Fan, Q. *et al.* (2009) Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M. *Blood*, **114**, 174-80.
31. Lim, E.T., Würtz, P., Havulinna, A.S., Palta, P., Tukiainen, T., Rehnström, K., Esko, T., Mägi, R., Inouye, M., Lappalainen, T., *et al.* (2014) Distribution and medical impact of loss-of-function variants in the Finnish founder population. *PLoS Genet.*, **10**, e1004494.
32. Southey, M.C., Park, D.J., Nguyen-Dumont, T., Campbell, I., Thompson, E., Trainer, A.H., Chenevix-Trench, G., Simard, J., Dumont, M., Soucy, P. *et al.* (2013) COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Res.*, **15**, 402.
33. Hosmer, D.W. and Lemeshow, S. (1989) *Applied Logistic Regression*, New York (USA).

34. Normand, S.L. (1999) Tutorial in Biostatistics. Meta-analysis: formulating, evaluating, combining and reporting. *Stat. Med.*, **18**, 321-359.
35. Mehta, C.R., Patel, N. and Senchaudhuri, P. (2000) Efficient Monte Carlo methods for conditional logistic regression. *J. Am. Stat. Assoc.*, **95**, 99-108.
36. Huelga, S.C., Vu, A.Q., Arnold, J.D., Liang, T.Y., Liu, P.P., Yan, B.Y., Donohue, J.P., Shiue, L., Hoon, S., Brenner, S. *et al.* (2012) Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. *Cell Rep.*, **1**, 167-178.
37. Bi, C. and Rogan, P.K. (2004) Bipartite pattern discovery by entropy minimization-based multiple local alignment. *Nucleic Acids Res.*, **32**, 4979-4991.
38. Olsen, R.K., Broner, S., Sabaratnam, R., Doktor, T.K., Andersen, H.S., Bruun, G.H., Gahrn, B., Stenbroen, V., Olpin, S.E., Dobbie, A. *et al.* (2014) The ETFDH c.158A>G variation disrupts the balanced interplay of ESE- and ESS-binding proteins thereby causing missplicing and multiple Acyl-CoA dehydrogenation deficiency. *Hum. Mutat.*, **35**, 86-95.
39. Fackenthal, J.D., Cartegni, L., Krainer, A.R. and Olopade, O.I. (2002) BRCA2 T2722R is a deleterious allele that causes exon skipping. *Am. J. Hum. Genet.*, **71**, 625-631.
40. Bruun, G.H., Doktor, T.K. and Andresen, B.S. (2013) A synonymous polymorphic variation in ACADM exon 11 affects splicing efficiency and may affect fatty acid oxidation. *Mol. Genet. Metab.*, **110**, 122-128.
41. Pastor, T. and Pagani, F. (2011) Interaction of hnRNPA1/A2 and DAZAP1 with an Alu-derived intronic splicing enhancer regulates ATM aberrant splicing. *PLoS One*, **6**, e23349.

42. Colombo, M., De Vecchi, G., Caleca, L., Foglia, C., Ripamonti, C.B., Ficarazzi, F., Barile, M., Varesco, L., Peissel, B., Manoukian, S. *et al.* (2013) Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations. *PLoS One*, **8**, e57173.
43. Bakker, S.T., van de Vrugt, H.J., Rooimans, M.A., Oostra, A.B., Steltenpool, J., Delzenne-Goette, E., van der Wal, A., van der Valk, M., Joenje, H., te Riele, H. *et al.* (2009) Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M. *Hum. Mol. Genet.*, **18**, 3484-3495.
44. Bogliolo, M., Schuster, B., Stoepker, C., Derkunt, B., Su, Y., Raams, A., Trujillo, J.P., Minguillon, J., Ramirez, M.J., Pujol, R. *et al.* (2013) Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. *Am. J. Hum. Genet.*, **92**, 800-806.
45. Castella, M., Pujol, R., Callen, E., Trujillo, J.P., Casado, J.A., Gille, H., Lach, F.P., Auerbach, A.D., Schindler, D., Benitez, J. *et al.* (2011) Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. *Blood*, **117**, 3759-3769.

Legends to Figures

Figure 1. Sequencing analysis of the *FANCM* gene and transcript. (a) Genomic DNA fragment PCR amplified using both primers in exon 22 from an LCL carrying the c.5791C>T mutation. (b) cDNA fragment amplified by PCR using a forward primer in exon 22 and a reverse primer in exon 23. A strong reduction in the expression of the mutant allele was observed in both cycloheximide treated and untreated cells. cDNA from a non carrier individual was used as a control. The position of the mutation is indicated by the arrows. Identical results were observed in an additional mutated LCL.

Figure 2. Analysis of the effect of the *FANCM* c.5791C>T mutation on RNA. (a) Sequence logo of hnRNP A1 binding sites generated as described in materials and methods. The opal codon (TGA, boxed) introduced by the *FANCM* c.5791C>T mutation (in bold red) is contained at positions 1-3 of the hnRNP A1 binding site encompassing nucleotides c.5790_5795. The hnRNP A1 binding-site strength computed by the ASSEDA software for the normal and mutated sequences are reported. (b) Agarose gel electrophoresis of the RT-PCR products using a forward primer in exon 21, and a reverse primer in exon 23. M, molecular marker (Φ X-174 *HaeIII* digested); 1, no template as a negative control for PCR; 2, genomic DNA as a negative control for the specificity of cDNA amplification; 3 and 4, cDNAs from LCLs carrying the c.5791C>T mutation, 5-14, cDNAs from LCLs derived from 10 mutation negative individuals, used as reference controls. The sizes of the full-length (FL) and Δ exon22 (Δ 22) transcripts are indicated. (c) Sequence of the aberrant band excised from the gel showing the skipping of the entire exon 22. (d) Western blot

analysis of biotin RNA-hnRNP A1 protein pull down using a goat polyclonal antibody. The sequence of the used RNA oligonucleotides encompassing *FANCM* positions r.5779_5804 are reported, with the r.5791C>U mutation in bold red, the opal codon enlightened in light grey and the predicted hnRNP A1 binding site created by the mutation boxed in red. As a control for the pull-down efficiency and specificity, we used an antibody against the ELAVL1/HuR protein for which a binding site, boxed in green, is predicted in both RNA oligonucleotides. Input, 10% of total HeLa cell line extract used in the pull down assay. No, no RNA used as a negative control; 1, normal RNA; 2, RNA carrying the r.5791C>U mutation. The results shown here are representative of two independent experiments.

Figure 3. Functional studies of the *FANCM* mutation. **(a)** Analysis of cellular MMC sensitivity. MEFs expressing $\Delta 22$ -*FANCM* allele (*Fancm*^{-/-} + $\Delta 22$ *FANCM*) are more sensitive to MMC than the cell expressing the wt *FANCM* allele (*Fancm*^{-/-} + wt *FANCM*). Not transduced MEFs (MEF *Fancm*^{-/-}) and MEF *Fancm*^{-/-} expressing a *FANCM* with loss-of-function mutation p.S724X (*Fancm*^{-/-} + stop *FANCM*) are used as controls (N=3; Error=SD). **(b)** Chromosome fragility induced by DEB treatment. *Fancm*^{-/-} + $\Delta 22$ *FANCM* and *Fancm*^{-/-} + stop *FANCM* cells show higher chromosome fragility than *Fancm*^{-/-} + wt *FANCM*. Twenty metaphases were analyzed for chromosome breaks. Results are represented as Mean number of breaks per cells and the error bars are SEM.

Table 1. Number and frequency of mutation carriers and non-carriers in cases and controls.

Geographical group	Country	Cases			Controls		
		Carriers	Non-carriers	Freq%	Carriers	Non-carriers	Freq%
South/Western Europe	Italy	6	2209	0.27	1	1483	0.07
	France	5	1570	0.32	1	1323	0.08
	Spain	3	751	0.40	0	286	NA
	All	14	4530	0.31	2	3092	0.06
Non-South/Western Europe	Germany	0	1636	NA	1	1899	0.05
	Australia	3	1235	0.24	1	1164	0.09
	USA	0	517	NA	0	322	NA
	Sweden	0	484	NA	0	0	NA
	The Netherlands	1	215	0.46	0	144	NA
	All	4	4087	0.10	2	3529	0.06
All populations	Total	18	8617	0.21	4	6621	0.06

NA, not applicable.

Table 2. Meta-analysis of the study-results from countries with mutation carriers in both cases and controls.

Country	Cases			Controls			OR	95% CI	P-value
	Carriers	Non-carriers	Freq%	Carriers	Non-carriers	Freq%			
Italy	6	2209	0.27	1	1483	0.07	4.03	0.48–33.47	0.197
France	5	1570	0.32	1	1323	0.08	4.21	0.49–36.10	0.189
Australia	3	1235	0.24	1	1164	0.09	2.82	0.24–27.13	0.369
Pooled	14	5014	0.28	3	3970	0.08	3.67	1.04–12.87	0.043

OR, Odds Ratio; CI, confidence interval.

Abbreviations

CI, confidence interval; DEB, diepoxybutane; EBV, Epstein-Barr virus; FA, Fanconi Anemia; LCL, lymphoblastoid cell line; MEFs, mouse embryonic fibroblasts; MMC, mitomycin C; NAS, nonsense associated altered splicing; NMD, nonsense mediated decay; nt, nucleotide; OR, odds ratio; RT-PCR, reverse transcriptase PCR.





